Century Therapeutics Statistics Share Statistics Century Therapeutics has 86.39M
shares outstanding. The number of shares has increased by 1.7%
in one year.
Shares Outstanding 86.39M Shares Change (YoY) 1.7% Shares Change (QoQ) 0.13% Owned by Institutions (%) 32.96% Shares Floating 41.5M Failed to Deliver (FTD) Shares 21 FTD / Avg. Volume n/a
Short Selling Information The latest short interest is 1.46M, so 1.69% of the outstanding
shares have been sold short.
Short Interest 1.46M Short % of Shares Out 1.69% Short % of Float 2.52% Short Ratio (days to cover) 2.11
Valuation Ratios The PE ratio is -0.63 and the forward
PE ratio is -0.41.
Century Therapeutics's PEG ratio is
0.02.
PE Ratio -0.63 Forward PE -0.41 PS Ratio 12.06 Forward PS 9.2 PB Ratio 0.49 P/FCF Ratio -0.72 PEG Ratio 0.02
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Century Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 1.5,
with a Debt / Equity ratio of 0.33.
Current Ratio 1.5 Quick Ratio 1.5 Debt / Equity 0.33 Debt / EBITDA -0.48 Debt / FCF -0.49 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $47.06K Profits Per Employee $-904.04K Employee Count 140 Asset Turnover 0.02 Inventory Turnover n/a
Taxes Income Tax 1.79M Effective Tax Rate -1.43%
Stock Price Statistics The stock price has increased by -68.15% in the
last 52 weeks. The beta is 1.78, so Century Therapeutics's
price volatility has been higher than the market average.
Beta 1.78 52-Week Price Change -68.15% 50-Day Moving Average 0.55 200-Day Moving Average 0.71 Relative Strength Index (RSI) 44.45 Average Volume (20 Days) 899,495
Income Statement In the last 12 months, Century Therapeutics had revenue of 6.59M
and earned -126.57M
in profits. Earnings per share was -1.61.
Revenue 6.59M Gross Profit 6.59M Operating Income -138.14M Net Income -126.57M EBITDA -111.47M EBIT -124.78M Earnings Per Share (EPS) -1.61
Full Income Statement Balance Sheet The company has 58.44M in cash and 53.83M in
debt, giving a net cash position of 4.61M.
Cash & Cash Equivalents 58.44M Total Debt 53.83M Net Cash 4.61M Retained Earnings -782.34M Total Assets 284.69M Working Capital 145.22M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -110.14M
and capital expenditures -154K, giving a free cash flow of -110.29M.
Operating Cash Flow -110.14M Capital Expenditures -154K Free Cash Flow -110.29M FCF Per Share -1.4
Full Cash Flow Statement Margins Gross margin is 100%, with operating and profit margins of -2096.48% and -1920.87%.
Gross Margin 100% Operating Margin -2096.48% Pretax Margin -1893.7% Profit Margin -1920.87% EBITDA Margin -1691.79% EBIT Margin -2096.48% FCF Margin -1673.84%
